Home > Inhibitors & Agonists > Cell Cycle/DNA Damage > Polo-like Kinase (PLK)
Cat. No. Product name CAS No.
DC11635 Poloxin-2

A potent, selective PLK1 PBD inhibitor with IC50 of 1.36 uM.

1807690-39-6
DC7083 Bi 2536 Featured

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3; BI2536 also is a BRD4 inhibitor(IC50= 25 nM).

755038-02-9
DC10011 Centrinone-B

Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM).

1798871-31-4
DC8609 GW843682X Featured

GW843682X is a cell-permeable thiophene-benzimidazole compound and reversible PLK inhibitor

660868-91-7
DC8768 HMN-214 Featured

HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.

173529-46-9
DC9594 Poloxin Featured

Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.

321688-88-4
DC7265 Rigosertib Featured

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM; shows 30-fold greater selectivity against PLK2 and no activity to PLK3.

1225497-78-8
DC7187 Volasertib(BI6727) Featured

Volasertib(BI6727) is a highly potent PLK1 inhibitor with an IC50 of 0.87 nM; shows 6- and 65-fold greater selectivity against Plk2 and Plk3.

755038-65-4
DC8598 PLK1 inhibitor GSK461364 Featured

GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.

929095-18-1
DC45827 BTO-1

BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications.

40647-02-7
DC45897 Volasertib trihydrochloride

Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models.

946161-17-7
DC47377 PLK1-IN-2

PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.

2640254-52-8
DC70300 CFI-400945

CFI-400945 is a potent, highly selective PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.

1338806-73-7
DC70301 CFI-400945 fumarate

CFI-400945 is a potent, highly selective, orally available PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.

1616420-30-4
Page 1 / Total 1 FirstPrevNextLastGoto